In June 2025, Daiichi Sankyo and AstraZeneca received approval for its use in adult patients with locally advanced or metastatic EGFR-mutated NSCLC who had previously undergone EGFR-targeted therapy and platinum-based chemotherapy. The broader adoption of TROP2 ADCs in NSCLC remains uncertain. While AstraZeneca and Daiichi Sankyo had initially withdrawn their wider marketing application for DATROWAY in NSCLC, its approval for EGFR-mutated cases represents a first-in-class achievement and an essential milestone in the field. Learn more about the TROP2 ADCs in NSCLC @ TROP2 ADCs in NSCLC Market Size TROP2 ADCs in NSCLC Competitive Landscape Some of the TROP2 ADCs in NSCLC in clinical trials include TRODELVY (sacituzumab govitecan) (Gilead Sciences), sacituzumab tirumotecan (Merck and Kelun-Biotech), DB-1305/BNT325 (Dualitybio/BioNTech), OBI-992 (OBI Pharma), and others.